Sector News

Boehringer aims to cut up to 600 jobs in Germany

September 23, 2014
Life sciences
(Reuters) – Drugmaker Boehringer Ingelheim said it plans to cut up to 600 jobs in Germany, citing healthcare budget cuts in the United States and a stricter reimbursement regime in Germany.
 
The unlisted family-controlled group, which collaborates on diabetes drugs with Eli Lilly, said in a statement on Tuesday the cutbacks were part of a drive to reduce costs in Germany by 15 percent or 450 million euros ($580 million).
 
The company, which makes stroke prevention pill Pradaxa, plans to cut between 500 and 600 jobs in Germany by the end of 2016, seeking to avoid forced redundancies.
 
Of its global workforce of 47,500, the group employs about 14,000 in Germany.
 
(1 US dollar = 0.7759 euro) (Reporting by Ludwig Burger; Editing by David Holmes)

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend